The present study offers a new strategy to increase the initial clinical response rate in EGFR‐mutated lung cancer patients by providing a molecular rationale for using EGFR‐TKI in combination with AKT inhibitor in patients harboring high RHOB tumor levels. The gene discussed is RHOB; the disease is neoplasm.